Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Amy Paller
Northwestern University at Chicago, Department: Dermatology
Should you be removed from our database? Contact us at [email protected]. Read more below.
AuraSense, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This research is to develop efficient approaches to use gold nanoparticles within topical creams to effect antisense inhibition of gene expression in the elidermis. Similar therapeutic approaches using engineered nanoparticles are the goal of the biotechnology company AuraSense, in which Dr. Paller discloses equity interests. Given the close relationship of the work and goals of AuraSense and this proposal, continued development of these topically applied nanoparticles funded through this grant may result in a perceived conflict of interest that should be managed.
Topical Delivery of siRNA Nanconjugates: Suppressing Epidermal Hyperplasia
Small interfering RNAs (siRNAs) are a widely used research tool to inhibit the expression of genes, but the delivery of siRNAs to humans, including through topical application for skin disease, is a significant challenge. We have developed gold nanoparticles densely coated with siRNAs (siRNA-Au NPs) and have shown their ability to penetrate the stratum corneum and knock down gene expression in mouse and human skin. The results of this proposed preclinical investigation that seeks to reverse pathologic skin thickening will establish polyvalent siRNA-gold nanoparticles as a new modality for treating skin disorders.
Filed on November 22, 2013.
Tell us what you know about Amy Paller's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Amy Paller filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Amy Paller | Northwestern University at Chicago | Conflict of Interest | Exicure | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.